HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Medbanks Network Technology - PHIP Updates: The Business Model Has yet to Be Verified

Yue Yuen Industrial Holdings (551.HK) - Challenging Prospects Overshadow Undervaluation

China Healthcare Weekly (Dec.9) - COVID Policy Update, Biotech Growth Curve, HKEX Chapter 18A Review

Sichuan Kelun Pharmaceutical (002422.CH) - The Deal with Merck Brightens the Outlook; A Dark Horse?

China to End Zero COVID Policy? - Reexamine the Reopening Timeline and Potential Impact

Pre-IPO Shanghai Chicmax Cosmetic - PHIP Updates: Declining Performance and Challenging Outlook

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Clover Biopharmaceuticals / Equity Capital Markets

<ul>
<li>Clover is placing 128 million shares, raising an estimated HK$500.5 million in net proceeds, which was released right after Clover’s lead COVID-19 vaccine was included for emergency use in China.</li>
<li>The COVID-19 vaccine would be the only hope for Clover in the short term. There could be big upside potential in share price if this vaccine could be successfully commercialized.</li>
<li>After Clover successfully develops a vaccine and goes through the whole commercialization process, it won’t be at the same level as those enterprises with no commercial products on the market.</li>
</ul>


Clover is placing 128 million shares, raising an estimated HK$500.5 million in net proceeds, which was released right after Clover’s lead COVID-19 vaccine was included for emergency use in China.
The COVID-19 vaccine would be the only hope for Clover in the short term. There could be big upside potential in share price if this vaccine could be successfully commercialized.
After Clover successfully develops a vaccine and goes through the whole commercialization process, it won’t be at the same level as those enterprises with no commercial products on the market.


Beijing Wantai Biological Phar (603392 CH)

Clover Biopharmaceuticals (2197.HK) Placement - A Good Bet